tokens: Even though , excluding patient Epi203 ( harboring TP53 Arg175His and Arg95Ter CHEK2 mutation ) as well as other patients harboring TP53 L2 / L3 mutations ( n = 129 ) , CHEK2 mutations ( n = 4 in total ) predicted for resistance to doxorubicin and epirubicin therapy ( p = 0 . 030 ) .